Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

395
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
395
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

59
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
59
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

645
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
645
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

411
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
411
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

345
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
345
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

605
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
605

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Predicting First-in-Human Pharmacokinetics: Comparative Evaluation of Standard PBPK, High-Throughput PBPK, and Machine Learning.

Molecular pharmaceutics·2026
Same author

Physiologically Based Biopharmaceutics Modelling-Best Scientific Practices to Define Drug Product Performance, Latest Regulatory and Industry Perspectives: Workshop Summary Report.

Pharmaceutics·2026
Same author

Sponsor Initiated Requests to Delay Pediatric Postmarketing Studies.

Pharmaceutical medicine·2026
Same author

Population Pharmacokinetics and Dosing Simulations of Pentobarbital in the Pediatric Population.

Journal of clinical pharmacology·2026
Same author

Effect of Incentivizing Pediatric Studies on the Development of Pediatric-Friendly Formulations.

The AAPS journal·2026
Same author

Overcoming the Challenges of Viscous Simulated Fed State Media with a Computerized Numerical Control Tablet Disintegration and Dissolution Tester.

AAPS PharmSciTech·2026

相关实验视频

Updated: Mar 11, 2026

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

6.2K

PQRI研讨会:儿童药物配方开发中的模型信息化药物开发 (MIDD) 方法.

Gilbert J Burckart1, Susan Abdel-Rahman2, Caleb Choi2

  • 1Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Bldg 51 Rm 3184, 10903 New Hampshire Ave, Silver Spring, Maryland, 20903, USA. gilbert.burckart@fda.hhs.gov.

The AAPS journal
|March 10, 2026
PubMed
概括

基于模型的药物开发 (MIDD) 推进了儿科配方. 新的生物相关模型改善了儿科患者药物吸收预测,有助于监管提交.

关键词:
生物等价性 生物等价性生物相关的生物相关.口服配方是一种口服配方.儿科 儿科 儿科 儿科基于生理学的生物制药建模.

更多相关视频

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.5K
Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
07:44

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

1.0K

相关实验视频

Last Updated: Mar 11, 2026

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM
13:54

A Workflow for Lipid Nanoparticle LNP Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models SVEM

Published on: August 18, 2023

6.2K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.5K
Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device
07:44

Establishment of Orthotopic Patient-derived Xenograft Models for Brain Tumors using a Stereotaxic Device

Published on: May 2, 2025

1.0K

科学领域:

  • 药理学和制药科学 药理学和制药科学
  • 药物开发 药物开发
  • 儿科医学 儿科医学

背景情况:

  • 儿科配方开发需要了解影响药物相互作用的本体发生相关过程.
  • 目前用于儿科药物吸收建模的方法需要提高准确性.

研究的目的:

  • 审查儿科配方模型信息化药物开发 (MIDD) 的进展.
  • 讨论新的生物相关模型及其在儿科药物开发中的应用.
  • 识别儿科吸收过程中的知识差距.

主要方法:

  • 关于MIDD在儿科配方开发中的方法的虚拟研讨会.
  • 讨论溶解测试及其在建模儿科药物吸收中的作用.
  • 对儿科生物相关模型和基于生理学的建模的审查.

主要成果:

  • 在理解影响儿科药物配方的本体发生相关过程方面取得了进展.
  • 儿科生物相关模型为儿科患者提供更现实的溶解数据.
  • 这些模型有助于生成用于监管提交的数据.

结论:

  • 对于推进儿科配方开发,MIDD方法至关重要.
  • 增强的生物相关和基于生理学的模型改善了药物吸收的预测.
  • 为了优化配方,需要对儿科吸收过程进行进一步的研究.